This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Link between effectiveness and cost data
The costing was retrospectively undertaken on the same patient sample as that used in the effectiveness study.
Study sample
In all, 63 patients (42 men, mean age 52 years, age range: 23-78) received ESWL treatment. Of those, 19 had mid-(mean stone size 63mm?2) and 44 lower (mean stone size 46mm?2) ureteric calculi. Mid-ureteric (mean stone size 50mm?2) calculi were treated either with the patient prone (12), or supine (7) and all lower (mean stone size 47mm?2) ureteric stones were treated with the patient prone. In all, 105 patients received URS treatment. Of these, 25 had midand 80 lower ureteric calculi. All URS were performed with the patient under general (17) or spinal (87) anaesthesia. Power calculations to determine the sample size were not undertaken.
Effectiveness results
ESWL for mid-and lower ureteric calculi showed a success rate of 90% and 81%, respectively, compared with 96% and 99% for URS. Patients treated with URS were stone-free within 2 days whereas patients treated with ESWL needed up to 4 months. The re-treatment rates were 50% in both mid and lower ureteric calculi for the ESWL group compared with 12% (mid) and 7% (lower) for the URS group. Five of 19 patients with residual fragments after USWL for midureteric stones were re-hospitalized because of fever (3 colic and 2 nephrostomy catheter placed) for a mean of 4 days. Two of the 44 patients with lower ureteric calculi were re-hospitalized for a mean of 5 days because of fever and progressive dilatation. In one patient the ureter was perforated during URS. No other serious complications occurred and no patient had to be re-hospitalized.
Clinical conclusions
ESWL provides a noninvasive, simple and safe option for the treatment of mid-and lower ureteric calculi, provided that the stones are < 50mm?2; larger stones are best treated by URS.
Measure of benefits used in the economic analysis
No summary benefit measure was used in the analysis and as such the benefits are considered to be the same as the outcome measures.
